AngioDesign Ltd Information

AngioDesign is a drug discovery company developing the first truly-novel, next-generation combination inhibitors (C-domain ACE, C-domain ACE/NEP, N-domain ACE) with the potential to treat a number of the most important conditions impacting human health today, including heart failure, hypertension and fibrosis. Angiotensin-converting enzyme was shown by AngioDesign's founders to consist of two similar but non-identical N- and C-domains that each contain an active site with different properties. Detailed knowledge of these differences is essential for the design and synthesis of novel domain-selective inhibitors. AngioDesign's drug discovery platform is focused on the rational design and development of improved, next-generation drugs for proven disease targets and its initial focus is on the development of inhibitors of angiotensin-converting enzyme.